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Abstract
Background: The World Health Organization (WHO) recommends that tuberculosis (TB) patients receive directly observed
therapy (DOT). Randomized controlled trials have not consistently shown that this practice improves TB treatment success
rates. In Thailand, one of 22 WHO-designated high burden TB countries, patients may have TB treatment observed by a
health care worker (HCW), family member, or no one. We studied whether DOT improved TB treatment outcomes in a
prospective, observational cohort.
Methods and Findings: We prospectively collected epidemiologic data about TB patients treated at public and private
facilities in four provinces in Thailand and the national infectious diseases hospital from 2004–2006. Public health staff
recorded the type of observed therapy that patients received during the first two months of TB treatment. We limited our
analysis to pulmonary TB patients never previously treated for TB and not known to have multidrug-resistant TB. We
analyzed the proportion of patients still on treatment at the end of two months and with treatment success at the end of
treatment according to DOT type. We used propensity score analysis to control for factors associated with DOT and
treatment outcome. Of 8,031 patients eligible for analysis, 24% received HCW DOT, 59% family DOT, and 18% self-
administered therapy (SAT). Smear-positive TB was diagnosed in 63%, and 21% were HIV-infected. Of patients either on
treatment or that defaulted at two months, 1601/1636 (98%) patients that received HCW DOT remained on treatment at
two months compared with 1096/1268 (86%) patients that received SAT (adjusted OR [aOR] 3.8; 95% confidence interval [CI]
2.4–6.0) and 3782/3987 (95%) patients that received family DOT (aOR 2.1; CI, 1.4–3.1). Of patients that had treatment success
or that defaulted at the end of treatment, 1369/1477 (93%) patients that received HCW DOT completed treatment
compared with 744/1074 (69%) patients that received SAT (aOR 3.3; CI, 2.4–4.5) and 3130/3529 (89%) patients that received
family DOT (aOR 1.5; 1.2–1.9). The benefit of HCW DOT compared with SAT was similar, but smaller, when comparing
patients with treatment success to those with death, default, or failure.
Conclusions: In Thailand, two months of DOT was associated with lower odds of default during treatment. The magnitude
of benefit was greater for DOT provided by a HCW compared with a family member. Thailand should consider increasing its
use of HCW DOT during TB treatment.
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Introduction
Despite the widespread availability of cheap, effective treat-
ment, tuberculosis (TB) remains a major cause of severe illness and
death, with an estimated nine million new cases and two million
deaths occurring annually.[1] One barrier to global TB control is
the long duration of TB treatment—a minimum of six months—
which frequently results in patients taking their medications
erratically or not at all.[2] Non-adherence to TB medications
decreases the chances of cure, increases the risk of relapse after
treatment, and selects for drug-resistant TB strains.[3] Directly
observing TB patients taking their anti-TB therapy, either daily or
several times per week, was first piloted in the 1950s as way to
insure adherence and treatment completion.[2] In 1994, based on
the reported success of directly observed therapy (DOT) in
increasing treatment completion rates and preventing drug
resistance, the World Health Organization (WHO) adopted
DOT as a principal component of its global TB control
PLoS ONE | www.plosone.org 1 August 2008 | Volume 3 | Issue 8 | e3089strategy.[4] Current technical manuals define DOT as direct
supervision of ‘‘medication ingestion…by a treatment supporter
who is acceptable and accountable to the patient and to the health
system.’’[5]
Although WHO and other international agencies strongly
advocate DOT, controversy remains whether its benefits have
been proven. Randomized controlled trials (RCT) have shown
either modest or no benefit of DOT in improving TB treatment
success rates, and a meta-analysis of 10 RCTs concluded that the
evidence base for WHO’s DOT policy is insufficient.[6] Advocates
of DOT have argued that the RCTs and this meta-analysis
evaluated the wrong endpoint. The effectiveness of DOT, it has
been argued, should be judged by how well it prevents drug
resistance, specifically to rifampin, and not by improvements in
treatment success rates.[7] Others contend that the scientific
literature supporting DOT has been weakened by studies
involving ‘‘sloppy’’ DOTS; the RCTs, it has been argued, were
under-powered to show an improvement in treatment success
rates, because the programs studied had sub-standard TB
programs.[8]
While RCTs are considered the gold standard for measuring the
efficacy of a biomedical intervention, prospective observational
studies are required to evaluate the effectiveness of an intervention
applied to a large population in uncontrolled (i.e., real world)
settings.[9] Such studies are particularly necessary for an
intervention, such as DOT for TB treatment, that involves
multiple components of the health system and relies predom-
inantly on government health facilities in poor countries. Thailand
is a low middle-income country with the 17
th largest burden of TB
in the world.[1] Despite official adoption of the WHO TB control
strategy in 1997, TB rates in Thailand have failed to decline, likely
due to a generalized HIV epidemic and sub-optimal treatment
success rates.[10] In Thailand, patients are treated in both the
public and private sector, and different strategies for DOT,
including no DOT, are implemented. Using data prospectively
collected over two years, we evaluated the impact of different
DOT strategies on treatment outcomes in a large, diverse cohort
of TB patients.
Methods
Data Collection
In 2003, the United States Centers for Disease Control and
Prevention (U.S. CDC) began collaborating with the Thailand
Ministry of Public Health (MOPH), Japan’s Research Institute for
Tuberculosis (RIT), four provinces in Thailand (Bangkok, Ubon-
Ratchathani, Phuket, Chiang Rai), and the national infectious
diseases hospital (in Nonthaburi province) on the Thailand TB
Active Surveillance Network, a demonstration project involving
enhanced surveillance, monitoring, evaluation, and treatment of
TB in Thailand.[11]
For all patients with a diagnosis of TB in the national infectious
diseases hospital or any public or private facility in the four
provinces, public health staff recorded standardized epidemiologic
data, collected sputum specimens for microbiologic testing, and
offered HIV counseling and testing. Patient data was collected
prospectively from routine medical and laboratory records and
entered into an electronic database. Patient outcomes were
recorded through the end of TB treatment, which was usually
about six months after registration.
Patient Population
All persons registered for TB treatment were considered TB
patients, consistent with WHO guidelines.[12] In this study,
patients were eligible for analysis if they were registered for TB
treatment between 1 October 2004 to 30 September 2006, were
diagnosed with pulmonary TB, were not previously treated for TB
or transferred in from a different TB program, were not known to
have multidrug-resistant TB (MDR-TB), and had data recorded
about their treatment observer. We classified patients with extra-
pulmonary TB as ineligible, because the duration of treatment,
drug regimen, and classification of outcomes, such as failure, vary
depending on the location of disease.[12] We classified patients
with previous TB treatment or known MDR-TB as ineligible,
because such patients are known to have substantially different
treatment outcomes than patients never previously treated.[13]
Eligible patients were excluded from the analysis of treatment
outcomes if their TB diagnosis was changed after registration, they
were missing data about treatment status at two months (for the
two month outcome analysis), or they were missing data about
their final treatment outcome (for the end of treatment analysis).
For this study, patients with an outcome of ‘‘transferred out’’ or
patients still on treatment at the time of this analysis were
considered to have missing outcome data.
Definitions
We used standard WHO definitions to categorize patients
according to previous TB treatment history, type of TB, and
treatment outcome, and we classified any death which occurred
during TB treatment as a TB death.[12] Consistent with WHO
recommendations, sputum culture was not used to evaluate
treatment outcome.[12]
In the database, public health staff recorded the type of
treatment observer used during the first two months of TB
treatment. Staff were instructed to classify patients as having
health care worker (HCW) DOT if the patient had ingestion of
anti-TB medicine observed by a HCW at least five times per week,
and they were instructed to classify patients as having family DOT
if the patient had a family member educated about TB treatment
who was responsible for observing and recording ingestion of anti-
TB medicine. Data was only recorded about the type of observer
used during the first two months of treatment, because Thai
national guidelines only require DOT during the period in which
four drugs are administered. In actual practice, some facilities that
provided DOT did so throughout treatment. The decision to
allocate patients to different forms of DOT was made by
individual health care providers; no data was collected about
why different strategies were used in different patients.
Data Analysis
We divided patients into three groups: HCW DOT, family
DOT, or self-administered treatment (SAT). We compared the
association between type of DOT received and treatment outcome
at two months and at the end of TB treatment. For the two month
outcome analysis, patient outcomes were divided into on
treatment, died, or defaulted. We compared the proportion of
patients still on treatment at two months versus those that
defaulted and the proportion still on treatment versus those that
either died or defaulted, according to DOT type. For the end of
treatment outcome analysis, patient outcomes included successful
treatment (defined as cured or completed treatment), died,
defaulted, or failed. We compared the proportion of patients
successfully treated versus those that died, defaulted, or failed
treatment and the proportion of patients successfully treated versus
those that defaulted, according to DOT type. In both the two
month and end of treatment analysis, default was analyzed
separately, because DOT is postulated to help reduce rates of
default.[14]
Observed Therapy
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confidence interval (CI) for factors associated with the use of
HCW, family DOT, or SAT. Statistical significance was defined as
p,0.05. Because some groups of patients were more likely to
receive a specific type of DOT and some factors associated with
DOT use were also associated with treatment outcomes, we
analyzed the association between DOT and treatment outcomes
using propensity score analysis.
Propensity score analysis is used when the baseline character-
istics of patients in two exposure groups (for example, those
receiving HCW DOT vs. those receiving family DOT) are very
different.[15] In observational studies, propensity score analyses
can produce a more accurate estimate of the true association
between an intervention (e.g., DOT) and an outcome (e.g.,
treatment success) by combining factors associated with the
intervention into a composite variable, known as the propensity
score, and by dividing the study population into strata that differ
with respect to the likelihood of receiving the intervention, but are
mostly equal with respect to other covariates.[15,16] In this study,
we first developed a multivariate logistic regression model of
factors associated with DOT, constructed propensity scores based
on these factors, and then divided the patient population into
equally sized quintiles based on their propensity to receive DOT.
We used logistic regression to calculate adjusted odds ratios for the
association between treatment outcomes and DOT type control-
ling for the DOT propensity quintile. We used an identical
approach for 12 different analyses, i.e., three exposure compar-
isons (HCW vs. family DOT; family DOT vs. SAT; and HCW vs.
family DOT) analyzed in four different patient subsets (success vs.
death, default, or failure at the end of TB treatment; success vs.
default at the end of TB treatment; on treatment vs. death or
default at two months; and on treatment vs. default at two
months).
Because there were variables consistently associated with
successful treatment or type of DOT in all 12 analysis, we
included these in the calculation of propensity scores: age, gender,
marital status, Thai nationality, mobility (defined as not residing
for at least three of last six months in the same district), living in an
urban district, chronic cough, history of injection drug use, history
of being in prison, history of previous isoniazid (INH) preventive
therapy, diabetes, HIV infection, having a cavity on chest
radiograph, sputum culture positive for Mycobacterium tuberculosis,
treatment with a standardized regimen (e.g., WHO Category I),
and quarter of enrollment.
Ethical Review
The protocol for this demonstration project underwent ethical
review by the Thailand Ministry of Public Health and CDC and
was found to be surveillance and public health program
implementation, not human subjects research requiring oversight
by an institutional review board.
Results
Patients analyzed
Of 14,354 patients recorded in surveillance, 8,031 (56%) were
eligible for the analysis.[Figure 1] The most common reason for
non-eligibility was extra-pulmonary TB (22%). The end-of-
Figure 1. Patients included in the analysis.
doi:10.1371/journal.pone.0003089.g001
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treatment.
Characteristics Treatment observer type Total
Health care worker Family Self-Administered No. (%)
No. (%) No. (%) No. (%) (N=8,031)
(N=1,900) (N=4,725 (N=1,406)
Type of pulmonary TB
Smear-positive 1230 (65) 3072 (65) 730 (52) 5032 (63)
Smear-negative 662 (35) 1622 (34) 457 (32) 2741 (34)
Smear-unknown 8 (0) 31 (1) 219 (16) 258 (3)
Age
0–14 20 (1) 99 (2) 10 (1) 129 (2)
15–44 1180 (62) 2077 (44) 948 (67) 4205 (52)
45–64 503 (27) 1435 (30) 317 (23) 2255 (28)
.65 197 (10) 1110 (24) 127 (9) 1434 (18)
Missing 0 (0) 4 (0) 4 (0) 8 (0)
Gender
Male 1330 (70) 3091 (65) 880 (63) 5301 (66)
Female 570 (30) 1632 (35) 526 (37) 2728 (34)
Missing 0 (0) 2 (0) 0 (0) 2 (0)
Nationality
Thai 1747 (92) 4449 (94) 1162 (83) 7358 (92)
Non-Thai 153 (8) 269 (6) 241 (17) 663 (8)
Missing 0 (0) 7 (0) 3 (0) 10 (0)
Marital status
Married 1091 (57) 3068 (65) 543 (39) 4702 (59)
Non-Married 798 (42) 1610 (34) 632 (45) 3040 (38)
Missing 11 (1) 47 (1) 231 (16) 289 (3)
Living in an urban district
Urban district 877 (46) 1608 (34) 823 (59) 3308 (41)
Non-urban district 1000 (53) 3001 (64) 483 (34) 4484 (56)
Missing 23 (1) 116 (2) 100 (7) 239 (3)
Mobile population
*
Non-mobile 1560 (82) 3738 (79) 467 (33) 5765 (72)
Mobile 315 (17) 836 (18) 798 (57) 1949 (24)
Missing 25 (1) 151 (3) 141 (10) 317 (4)
Ever treated with isoniazid preventive therapy (IPT)
Previously treated with IPT 22 (1) 28 (1) 7 (1) 57 (1)
Not ever treated with IPT 1876 (99) 4688 (99) 1354 (96) 7918 (98)
Missing 2 (0) 9 (0) 45 (3) 56 (1)
Cough lasting .2 weeks at time of diagnosis
Cough .2 weeks 1404 (74) 3258 (69) 805 (57) 5467 (68)
No cough .2 weeks 487 (26) 1389 (29) 317 (23) 2193 (27)
Missing 9 (0) 78 (2) 284 (20) 371 (5)
Ever used injection drugs
Ever used injection drugs 80 (4) 88 (2) 36 (3) 204 (3)
Not ever used injection drugs 1769 (93) 4545 (96) 779 (55) 7093 (88)
Missing 51 (3) 92 (2) 591 (42) 734 (9)
In jail or prison
Previously in jail or prison 80 (4) 41 (1) 7 (0) 128 (2)
Not in jail/prison 1805 (95) 4671 (99) 1006 (72) 7482 (93)
Missing 15 (0) 13 (0) 393 (28) 421 (5)
Observed Therapy
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Health care worker Family Self-Administered No. (%)
No. (%) No. (%) No. (%) (N=8,031)
(N=1,900) (N=4,725 (N=1,406)
Living in migrant or refugee camp
In camp 83 (4) 19 (0) 10 (1) 112 (1)
Not in camp 1765 (93) 4626 (98) 844 (60) 7235 (90)
Unknown 52 (3) 80 (2) 552 (39) 684 (9)
Facility that made diagnosis
Private health facility 46 (3) 229 (5) 608 (43) 883 (11)
Government health facility 1853 (97) 4494 (95) 797 (57) 7144 (89)
Missing 1 (0) 2 (0) 1 (0) 4 (0)
Facility that provide treatment
Private health facility 10 (1) 172 (4) 604 (43) 786 (10)
Government health facility 1889 (9) 4551 (96) 802 (57) 7242 (90)
Missing 1 (0) 2 (0) 0 (0) 3 (0)
Diabetes mellitus
Diabetes 63 (3) 236 (5) 37 (3) 336 (4)
No diabetes 1459 (77) 3881 (82) 886 (63) 6226 (78)
Missing 378 (20) 608 (13) 483 (34) 1469 (18)
HIV status
Positive 433 (23) 983 (21) 300 (21) 1716 (21)
Negative 1322 (70) 2834 (60) 365 (26) 4521 (56)
Missing 145 (7) 908 (19) 741 (53) 1794 (22)
Chest radiograph
Normal 15 (1) 76 (1) 34 (2) 125 (2)
Not performed or results missing 103 (5) 550 (12) 63 (5) 716 (9)
Abnormal 1782 (94) 4099 (87) 1309 (93) 7190 (89)
Presence of a cavity 490 (28) 1164 (28) 272 (21) 1926 (27)
Sputum culture result
#
Growth of MTB 1118 (59) 2297 (49) 349 (25) 3764 (47)
No growth 400 (21) 686 (14) 127 (9) 1213 (15)
Not performed, contaminated, or grew NTM 382 (20) 1742 (37) 930 (66) 3054 (38)
Initial treatment prescribed
CAT I (2HRZE/4HR) 1785 (94) 4454 (94) 1126 (80) 7365 (92)
Other regimens 115 (6) 271 (6) 280 (20) 666 (8)
Period of the year
Oct.–Dec. 492 (26) 995 (21) 289 (20) 1776 (22)
Jan.–Mar. 506 (26) 1211 (26) 419 (30) 2136 (27)
Apr.–Jun. 454 (24) 1331 (28) 376 (27) 2161 (27)
Jul.–Sep. 447 (24) 1188 (25) 322 (23) 1957 (24)
Missing 1 (0) 0 (0) 0 (0) 1 (0)
Treatment outcome at the end of intensive phase
Smear-negative 1295 (68) 2937 (62) 416 (30) 4648 (58)
Smear-positive 51 (3) 131 (3) 46 (3) 228 (3)
Died 148 (8) 412 (9) 48 (3) 608 (8)
Default 35 (2) 206 (4) 173 (12) 414 (5)
Transferred out 86 (4) 177 (4) 70 (5) 333 (4)
Change of diagnosis 29 (2) 118 (3) 10 (1) 157 (2)
On treatment, smear unknown@ 256 (3) 721 (15) 640 (46) 1617 (20)
Missing 0 (0) 23 (0) 3 (0) 26 (0)
Table 1. cont.
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961 (12%) eligible patients that were recorded as still being on
treatment, as transferred out, or as changed diagnosis. The two
month outcome analysis included 7,515 patients, because we
excluded 516 (6%) eligible patients that had an outcome recorded
as transferred out, changed diagnosis, or missing.
Characteristics of eligible patients
Of the 8,031 patients eligible for the analysis, 24% received
HCW DOT, 59% family DOT, and 18% SAT.[Table 1]
Pulmonary TB was classified as smear-positive in 5,032 (63%);
overall, 47% had at least one sputum culture positive for
Mycobacterium tuberculosis. Most patients were male, aged 15–44
years, married, and residents of a non-urban district. HIV
infection was diagnosed in 1,716 (21%). Ten percent received
treatment in a non-government facility; 604 (43%) of patients
that received SAT were treated in a non-government facility.
The standard WHO category I regimen (two months of INH,
rifampin, pyrazinamide, and ethambutol, followed by four
months of INH and rifampin) was prescribed to 92%; data was
not available on the regimen prescribed to the other 8%. At two
months, 81% of patients were still on treatment, 8% died, and
5% defaulted; the remaining patients had outcomes of
transferred out (4%), or changed diagnosis (2%). At the end of
TB treatment, 66% had a successful outcome (cured or
completed), 23% had an unsuccessful outcome (death, default,
or failure), 6% transferred out, 2% changed diagnosis, and 4%
were still on treatment.
For the two month outcome analysis, the 516 patients excluded
from the analysis were more likely than the 7,515 included patients
to be mobile, to have known HIV status, and to have not had
sputum culture performed (p,0.05, all comparisons). Other
clinical and demographic characteristics were similar between
the included and excluded groups. For the end of treatment
analysis, the 961 excluded patients were more likely than the 7,070
included patients to have received SAT, to have not had sputum
culture performed, to live in an urban district, to be mobile,
and to be HIV-infected or HIV unknown (p,0.05, all
comparisons).[Table 2]
Outcomes at end of two months
When limited to patients who were on treatment, died, or
defaulted within two months of starting TB treatment, 1,601 (90%)
of 1,784 patients that received HCW DOT were still on treatment
at two months, compared with 1,096 (83%) of 1,316 patients that
received SAT (OR 1.8; CI, 1.4–2.2); when adjusted for propensity
score, the magnitude of association decreased, and was not
statistically significant (adjusted OR [aOR] 1.3; CI, 1.0–
1.7).[Table 3] No benefit was found for patients that received
family DOT vs. SAT (aOR 1.1; CI, 0.9–1.4). When comparing
HCW vs. family DOT in propensity score analysis, there was no
statistically significant difference in the proportion on treatment at
two months versus died or defaulted.
When we restricted the analysis to evaluate the impact of DOT
on default at two months, HCW DOT was strongly associated
with being on treatment at two months compared with SAT or
family DOT in both bivariate and propensity score analysis. In
patients that were either on treatment or defaulted at two months,
1,601 (98%) of 1,636 HCW DOT patients were on treatment at
two months compared with 3,782 (95%) of 3,987 family DOT
patients (aOR 2.1; CI, 1.4–3.1) and 1096 of 1,268 (86%) SAT
patients (aOR 3.8; CI, 2.4–6.0).
Outcomes at end of treatment
At the end of TB treatment, treatment success was associated
with HCW (aOR 1.6; CI, 1.3–2.0) or family DOT (aOR 1.3; CI,
1.1–1.5) compared with SAT, among patients with treatment
success, death, default, or failure. Patients who received HCW
DOT were not significantly more likely to have treatment success
compared with family DOT patients (aOR 1.1; CI, 0.9–1.2).
When we restricted the analysis to evaluate the impact of DOT on
only default at the end of TB treatment, HCW DOT was strongly
associated with treatment success compared with family DOT or
SAT in both bivariate and propensity score analysis. In patients
that had treatment success or default at the end of treatment,
1,369 (93%) of 1,477 HCW DOT patients had treatment success
compared with 3,130 (89%) of 3,529 family DOT patients (aOR
1.5; CI, 1.2–1.9) and 744 of 1,074 (69%) SAT patients (aOR 3.3;
CI, 2.4–4.5).
Characteristics Treatment observer type Total
Health care worker Family Self-Administered No. (%)
No. (%) No. (%) No. (%) (N=8,031)
(N=1,900) (N=4,725 (N=1,406)
Treatment outcome
Cured 877 (46) 1937 (41) 205 (14) 3019 (38)
Completed 492 (26) 1198 (25) 544 (39) 2234 (28)
Failure 17 (1) 74 (2) 13 (1) 104 (1)
Died 222 (12) 583 (12) 67 (5) 872 (11)
Default 108 (6) 401 (8) 332 (23) 841 (10)
Transfer out 121 (6) 245 (5) 100 (7) 466 (6)
Change of diagnosis 29 (1) 117 (2) 11 (1) 157 (2)
On treatment 34 (2) 170 (4) 134 (10) 338 (4)
*Mobile was defined as not living in the same district for at least three of the past six months.
#MTB denotes Mycobacterium tuberculosis, and NTM denotes non-tuberculous mycobacteria.
@Patients who were on treatment, but had missing data about whether their sputum smears were positive or negative.
doi:10.1371/journal.pone.0003089.t001
Table 1. cont.
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At Two Months At End of Treatment
Excluded Included Excluded Included
No. (%) No. (%) No. (%) No. (%)
(N=516) (N=7,515) (N=961) (N=7,070)
DOT
HCW DOT 115 (22) 1788 (24) 184 (19) 1716 (24)
Family DOT 318 (62) 4407 (59) 532 (55) 4193 (59)
SAT 83 (16) 1323 (17) 245 (26) 1161 (17)
Age
0–14 11 (2) 118 (2) 22 (2) 107 (1)
15–44 292 (57) 3913 (52) 540 (56) 3665 (52)
45–64 114 (22) 2141 (28) 235 (24) 2020 (29)
.65 98 (19) 1336 (18) 162 (17) 1272 (18)
Missing 1 (0) 7 (0) 2 (0) 6 (0)
Gender
Male 335 (65) 4966 (66) 625 (65) 4676 (66)
Female 180 (35) 2548 (34) 335 (35) 2393 (34)
Missing 1 (0) 1 (0) 1 (0) 1 (0)
Nationality
Thai 463 (90) 6895 (92) 876 (91) 6482 (92)
Non-Thai 52 (10) 611 (8) 84 (9) 579 (8)
Missing 1 (0) 9 (0) 1 (0) 9 (0)
Marital status
Married 282 (55) 4420 (59) 506 (53) 4196 (59)
Non-Married 218 (42) 2822 (37) 395 (41) 2645 (37)
Missing 16 (3) 273 (4) 60 (6) 229 (3)
Living in an urban district
Urban district 226 (44) 3082 (41) 462 (48) 2846 (40)
Non-urban district 275 (53) 4209 (56) 459 (48) 4025 (57)
Missing 15 (3) 224 (3) 40 (4) 199 (3)
Mobile population
*
Mobile 211 (41) 1738 (23) 385 (40) 1564 (22)
Non-mobile 284 (55) 5481 (73) 514 (54) 5251 (74)
Missing 21 (4) 296 (4) 62 (6) 255 (40
Ever treated with isoniazid preventive therapy (IPT)
Previously treated with IPT 2 (0) 55 (1) 3 (0) 54 (1)
Not ever treated with IPT 512 (100) 7406 (98) 953 (99) 6965 (98)
Missing 2 (0) 54 (1) 5 (1) 51 (1)
Cough lasting .2 weeks at time of diagnosis
Cough .2 weeks 314 (61) 5153 (68) 576 (60) 4891 (69)
No cough .2 weeks 183 (35) 2010 (27) 280 (29) 1913 (27)
Missing 19 (4) 352 (5) 105 (11) 266 (4)
Ever used injection drugs
Ever used injection drugs 21 (4) 183 (2) 36 (4) 168 (2)
Not ever used injection drugs 462 (90) 6631 (88) 766 (80) 6372 (90)
Missing 33 (6) 701 (9) 159 (16) 575 (8)
In jail or prison
Previously in jail or prison 12 (2) 116 (2) 23 (2) 105 (1)
Not in jail/prison 489 (95) 6993 (93) 825 (86) 6657 (94)
Missing 15 (3) 406 (5) 113 (12) 308 (5)
Diabetes mellitus
Observed Therapy
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In this large, prospective observational study, we found that at
least two months of DOT was associated with improved TB
treatment outcomes. Although observation by either a HCW or
family member was beneficial, the greatest magnitude of benefit
was associated with HCW DOT and the greatest impact was on
treatment default rates.
This is the largest analytical study every published about the
impact of DOT on TB treatment outcomes. A major strength is that
it was conducted among a diverse patient population within the
existing public health care system in a high burden TB country.
Previous studies of DOT have been conducted at specialized centers
or, when community based, involved substantially smaller or more
homogenouspopulations.[6] Inthisstudy,over20%of patients were
HIV-infected, and patients from the private sector, urban and rural
districts, and migrant (non-Thai) populations were studied. We
applied rigorous statistical techniques to control for the propensity of
patients to receive DOT, adjusting for the fact that patients more
likely to be adherent may also be more likely to consent to DOT and
that DOT may be a marker for a healthcare facility with a better
performing TB treatment program.
We found that having a treatment observer was better than not
having a treatment observer in reducing default. Our findings
were internally consistent. Because we only recorded whether
DOT was provided for the first two months of treatment, we found
that the impact of DOT was greatest on default at two months.
Similarly, we found a gradient of impact for DOT, with HCW
DOT having a larger impact than family DOT, a finding we
would have expected given that HCWs are more likely to apply
DOT strictly.[17] We found less benefit when we analyzed
composite endpoints of default plus death, failure, or both. We
would not expect DOT to have a substantial impact on death,
because the primary risk factor for death during TB treatment in
Thailand is HIV, and anti-retroviral therapy is the strongest
determinant of survival in HIV-associated TB.[18] We also would
not expect DOT to have a substantial impact on treatment failure,
because rates of failure are low in Thailand, and, when it occurs,
failure is likely attributable to drug resistance.[19] Our findings are
also externally consistent with previous, smaller studies conducted
in Thailand and in other settings on the benefit, albeit small, of
DOT.[20–23] DOT by family members has also been shown to
produce similar outcomes as HCW DOT in one randomized
trial.[24]
At Two Months At End of Treatment
Excluded Included Excluded Included
No. (%) No. (%) No. (%) No. (%)
(N=516) (N=7,515) (N=961) (N=7,070)
Diabetes 15 (3) 321 (4) 40 (4) 296 (4)
No diabetes 414 (80) 5812 (77) 710 (74) 5516 (78)
Missing 87 (17) 1382 (18) 211 (22) 1258 (18)
HIV status
Positive 152 (30) 1564 (21) 260 (27) 1456 (20)
Negative 171 (33) 1623 (22) 372 (39) 4149 (59)
Missing 193 (37) 4328 (57) 329 (34) 1465 (21)
Chest radiograph
Abnormal 444 (86) 6746 (90) 836 (87) 6354 (90)
Normal 20 (4) 105 (1) 30 (3) 95 (1)
Not performed or results missing 52 (10) 664 (9) 95 (10) 621 (9)
Sputum culture result
#
Growth of MTB 135 (26) 3629 (48) 319 (33) 3445 (49)
No growth 88 (17) 1125 (15) 141 (15) 1072 (15)
Not performed, contaminated, or grew NTM 293 (57) 2761 (37) 501 (52) 2553 (36)
Initial treatment prescribed
CAT I (2HRZE/4HR) 463 (90) 6902 (92) 821 (85) 6544 (93)
Other regimens 53 (10) 613 (8) 140 (15) 526 (7)
Period of the year
Oct–Dec. 98 (19) 1678 (22) 145 (15) 1631 (23)
Jan.–Mar. 125 (24) 2011 (27) 188 (20) 1948 (28)
Apr.–Jun. 138 (27) 2023 (27) 235 (24) 1926 (27)
Jul.–Sep. 155 (30) 1802 (24) 392 (41) 1562 (22)
Missing 0 (0) 1 (0) 1 (0) 0 (0)
*Mobile was defined as not living in the same district for at least three of the past six months.
#MTB denotes Mycobacterium tuberculosis, and NTM denotes non-tuberculous mycobacteria.
doi:10.1371/journal.pone.0003089.t002
Table 2. cont.
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was conducted within the routine healthcare system. We did not
independently verify that patients recorded as receiving DOT
actually received DOT, nor did we measure the rigor with which
DOT was applied. Misclassification would most likely have
involved patients being recorded as receiving DOT but not
actually receiving it, which would bias our findings to a null
association.[17] Therefore, we think that this study presents a
conservative estimate of the benefit to DOT. Second, because of
the large number of analyses performed, we could not perfectly
balance all covariates when constructing propensity score
quintiles. Within a given quintile, all patients should be equally
likely to receive DOT (i.e., covariates should not be statistically
associated with receiving DOT within that quintile), and, across all
quintiles, less than 5% of covariates should be imbalanced.[15] In
our analysis, we occasionally found imbalances of greater than 5%
but less than 10%. We, therefore, also conducted traditional risk
factor adjusted logistic regression for all 12 analyses, and found
similar direction, magnitude, statistical significance, and precision
as the propensity score analysis (data not shown). Although both
statistical methods are valid, they can only adjust for measured
confounders; it is possible that unmeasured confounders are
responsible for the association between DOT and favorable
outcomes that we found. Third, we only collected data about
DOT use for the first two months of TB treatment. We are not
able to draw any conclusions about the impact, either positive or
negative, that providing DOT for the entire duration of treatment
might have. Finally, we excluded patients from the two month and
end of treatment analyses because of missing data. In some TB
programs, patients who transfer out but who do not have final
treatment outcomes reported as part of the original cohort are
considered to have defaulted. We believe that either counting
these patients as defaulters or excluding them would not change
our findings, because the proportion of eligible patients excluded
because of being transferred out was not substantial (359 [4.5%]
for the two month outcome; 466 [5.8%] for the end-of-treatment
outcome).
Despite the additional public health infrastructure provided
through this project, treatment outcomes remained far below
international targets. Some of this can be explained by the large
number of HIV-infected, sputum smear-negative, private practice,
and non-Thai patients included in our analysis. Nevertheless,
Thailand’s overall treatment success rates remain sub-optimal.
Although our findings of a strong benefit to DOT in reducing
default are not completely consistent with RCTs, they are highly
consistent with established public health experience, and, most
important, they are generalizable to the health system within
Thailand. Our study strongly suggests that Thailand’s national TB
Table 3. Bivariate and multivariate measures of association for successful TB treatment and health care worker observed, family
member observed, and self-administered therapy.
Treatment observer type Analysis method
No. with treatment success
# /
No. exposed Odds ratio
Population Studied (%) (95% confidence interval)
Outcomes Exposures
*
No. patients
analyzed
Health care
worker
Family
member
Self-
administered Bivariate
Propensity Score
Risk Adjustment
On treatment vs. death or
default at two months
HCW vs. SAT 3100 1601/1784
(90%)
— 1096/1316
(83%)
1.8 (1.4–2.2) 1.3 (1.0–1.7)
Family vs. SAT 5715 — 3782/4399
(86%)
1096/1316
(83%)
1.2 (1.0–1.5) 1.1 (0.9–1.4)
HCW vs. Family 6183 1601/1784
(90%)
3782/4399
(86%)
— 1.4 (1.2–1.7) 1.1 (0.9–1.3)
On treatment vs.
default at two months
HCW vs. SAT 2904 1601/1636
(98%)
— 1096/1268
(86%)
7.2 (4.9–10.4) 3.8 (2.4–6.0)
Family vs. SAT 5255 — 3782/3987
(95%)
1096/1268
(86%)
2.9 (2.3–3.6) 2.0 (1.5–2.7)
HCW vs. Family 5623 1601/1636
(98%)
3782/3987
(95%)
— 2.5 (1.7–3.6) 2.1 (1.4–3.1)
Success vs. death, default, or
failure at end of TB treatment
HCW vs. SAT 2870 1369/1716
(80%)
— 744/1154 (64%) 2.2 (1.8–2.6) 1.6 (1.3–2.0)
Family vs. SAT 5340 — 3130/4186
(75%)
744/1154 (64%) 1.6 (1.3–1.5) 1.3 (1.1–1.5)
HCW vs. Family 5902 1369/1716
(80%)
3130/4186
(75%)
— 1.3 (1.2–1.5) 1.1 (0.9–1.2)
Success vs. default at end of TB
treatment
HCW vs. SAT 2551 1369/1477
(93%)
— 744/1074 (69%) 5.6 (4.5–7.1) 3.3 (2.4–4.5)
Family vs. SAT 4603 — 3130/3529
(89%)
744/1074 (69%) 3.5 (3.0–4.1) 2.0 (1.6–2.4)
HCW vs. Family 4998 1369/1477
(93%)
3130/3529
(89%)
— 1.6 (1.3–2.0) 1.5 (1.2–1.9)
*HCW denotes health care worker directly observed therapy; family denotes family member directly observed therapy, and SAT denotes self-administered treatment
(i.e., no directly observed therapy).
#For outcomes at two months, patients ‘‘on treatment’’ are considered successfully treated.
doi:10.1371/journal.pone.0003089.t003
Observed Therapy
PLoS ONE | www.plosone.org 9 August 2008 | Volume 3 | Issue 8 | e3089program should strengthen its use of DOT and, wherever possible,
use HCWs to provide it. Because a large number of patients that
received SAT were treated in the private sector, efforts are also
needed to bring private sector practices in line with international
standards, including use of DOT.[5]
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